Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.

Key Points

• This research aims to determine if baseline interleukin-10 levels can predict treatment response to abatacept in early rheumatoid arthritis.
• Evaluated patients with early rheumatoid arthritis who were naive to disease-modifying antirheumatic drugs.
• Assessed changes in biomarkers and clinical outcomes with treatment involving abatacept and methotrexate.
• Compared results with those receiving placebo and methotrexate.
• Abatacept plus methotrexate led to a significant reduction in biomarkers associated with rheumatoid arthritis.
• Patients with high baseline interleukin-10 levels showed better treatment responses compared to those receiving placebo.
• Support for the mechanism of action for abatacept in targeted patients was demonstrated.